We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Breast Cancer Metastasis into the Brain Depends on a Specific MicroRNA

By LabMedica International staff writers
Posted on 21 Feb 2013
The ability of breast cancer cells to spread into the brain is controlled by the regulation of the gene KLF4 (Krueppel-like factor 4) by the microRNA (miRNA) miR-7. More...


Despite significant improvement in survival rates of patients with breast cancer, prognosis of metastatic disease is still bleak. While cancer stem-like cells (CSC) are considered to play a role in the spread of breast cancer, the exact pathologic role of CSCs has not yet been elucidated.

To better understand the molecular mechanisms that drive breast cancer metastasis investigators at the University of Mississippi Medical Center (Jackson, USA) performed microRNA (miRNA) profile analyses on CSCs isolated from metastatic breast cancer cell lines. MiRNAs are molecular fragments of about 20 nucleotides that block gene expression by attaching to molecules of messenger RNA (mRNA) in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA.

The investigators reported in the February 5, 2013, online edition of the journal Cancer Research that CSCs isolated from metastatic breast cell lines were significantly more metastatic than non-CSC populations in an organ-specific manner. The results of the miRNA profile analysis for these cells revealed that CSCs that were highly metastatic to bone and brain expressed significantly lower levels of miR-7 and that this miRNA was capable of modulating one of the essential genes for induced pluripotent stem cells, KLF4 (Krueppel-like factor 4).

High expression of KLF4 was significantly and inversely correlated to brain but not bone metastasis-free survival of patients with breast cancer, and the expression of miR-7 significantly suppressed the ability of CSCs to metastasize to brain but not to bone in an animal model. In addition, the expression of miR-7 and KLF4 were significantly down- or upregulated, respectively, in the tumor cells in brain metastatic lesions obtained from human patients.

“Recent research has shown that microRNAs are involved in tumor initiation and progression, and we hypothesized that they also may play a role in metastasis, particularly in relation to cancer stem-like cells,” said senior author Dr. Kounosuke Watabe, professor of microbiology and biochemistry at the University of Mississippi Medical Center. “We found that miR-7 is a metastasis suppressor in cancer stem-like cells,” said Dr. Watabe. “When we increased expression of miR-7 in cancer stem-like cells from metastatic human breast cancer cell lines, it suppressed their metastatic properties. High expression of KLF4 was inversely associated with brain metastasis-free survival but was not associated with bone metastasis. This was confirmed in an animal model when we found that expression of miR-7 significantly suppressed the ability of cancer stem-like cells to metastasize to the brain but not the bone. Cancer cells find the brain to be a kind of sanctuary where they can survive longer. It is possible that miR-7 and KLF4 may serve as diagnostic or prognostic markers, or therapeutic targets for the prediction of, or treatment of, brain metastasis.”

Related Links:
University of Mississippi Medical Center


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.